Five-Year Follow-Up Data for SPRYCEL(R) (dasatinib) 100 mg Once Daily Demonstrated 78 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imati

Paris (ots/PRNewswire) -

Five-year follow-up results were presented today from a Phase 3
randomised, open-label, dose-optimisation study of SPRYCEL(R)
(dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase
chronic myeloid leukaemia(CP-CML) adult patients resistant or
intolerant to imatinib mesylate. At five years, for patients
randomised to receive dasatinib 100 mg once daily (n=167), overall
survival was 78% (95% CI: 72%-85%) and progression-free survival was
57% (95% CI: 48%-67%). Five percent of patients (n=8) randomised to
dasatinib 100 mg once daily progressed to accelerated or blast phase
on study at five years of follow-up.

The five-year safety data from this study are consistent with the
previously-reported safety profile of dasatinib 100 mg once daily.
The cumulative incidence of grade 3/4 pleural effusion was 4%. Other
grade 3/4 adverse events (AEs) with cumulative rates greater than or
equal to 5% included neutropenia (36%), thrombocytopenia (24%),
leukopenia (18%), and anaemia (13%). The cumulative incidence rates
of the most common non-hematological AEs of all grades at five years
of follow-up were: headache (33%), diarrhoea (28%), fatigue (26%),
dyspnea (24%) and pleural effusion (24%).

These data were presented today at the 16th Congress of the
European Hematology Association (EHA) in London (Abstract # 0136).

"In this study, the five-year follow up data demonstrated the
long-term efficacy and consistent safety profile for SPRYCEL 100 mg
once daily in patients with CP-CML following prior imatinib therapy,"
said Neil Shah, MD, PhD, Assistant Professor, Division of
Hematology/Oncology, University of California, San Francisco and
principal investigator of the study. "Results from this SPRYCEL study
are important as they provide long-term follow up of patients with
CP-CML treated with SPRYCEL who are resistant or intolerant to
imatinib."

About Study CA180-034

Study CA180-034 was designed to assess the efficacy and safety of
dasatinib 100 mg once daily. The trial enrolled 670 CP-CML patients
with resistance (n=497) or intolerance (n=173) to imatinib who were
randomised to one of four treatment arms: 100 mg once daily (n=167),
50 mg twice daily (n=168), 140 mg once daily (n=167), and 70 mg twice
daily (n=168). In this heavily pre-treated population, the median
time from onset of CML to randomisation in patients on the 100mg once
daily arm was 55 months and 46% of these patients had more than three
years of prior imatinib treatment. Data on the primary endpoint of
the study, major cytogenetic response in imatinib-resistant patients,
have been previously reported. Thirty-four percent of patients
randomised to receive dasatinib 100 mg once daily remained on
treatment at 5 years.

About SPRYCEL

Dasatinib, an oral BCR-ABL inhibitor, was initially approved in
November 2006 by the European Commission for the treatment of adults
for all phases of CML (chronic, accelerated, or myeloid or lymphoid
blast phase) with resistance or intolerance to prior therapy
including imatinib. Dasatinib is also approved for the treatment of
adults with Philadelphia chromosome-positive acute lymphoblastic
leukaemia with resistance or intolerance to prior therapy. Since
then, dasatinib has been approved for this indication in more than 60
countries worldwide. In 2010, dasatinib 100 mg once daily was
approved by the FDA and European Commission for the treatment of
adult patients with newly diagnosed Ph+ CML in chronic phase. In the
U.S., dasatinib received accelerated FDA approval for this
indication. The effectiveness of dasatinib is based on cytogenetic
response and major molecular response rates. The first-line trial
(known as DASISION) is ongoing and further data will be required to
determine long-term outcome. Now, more than 50 countries have
approved dasatinib for this indication.

About Chronic Myeloid Leukaemia

CML is a slow-growing type of leukaemia in which the body
produces an uncontrolled number of abnormal white blood cells.[1] CML
accounts for 15% of all leukaemias.[2] Due to the ageing population,
the incidence of CML is increasing. The incidence is estimated at 1-2
cases per 100,000.[3]

CML occurs when pieces of two different chromosomes break off and
attach to each other. The new chromosome is called the
Philadelphia-positive chromosome, which contains an abnormal gene
called BCR-ABL that signals cells to make too many white blood cells.
There is no known cause for the genetic change that causes CML.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines that
help patients prevail over serious diseases.

About Otsuka Pharmaceutical Co., Ltd

Otsuka Pharmaceutical Co., Ltd is a successful, innovative,
fast-growing healthcare company that commercialises Otsuka-discovered
and other product opportunities globally, with a strong focus on and
commitment to neuroscience, cardiovascular, oncologic, and
gastrointestinal therapeutic treatments. Otsuka Pharmaceutical Co.,
Ltd is dedicated to improving patients' health and the quality of
human life. Otsuka Pharmaceutical Co., Ltd. is a wholly owned
subsidiary of Otsuka Holdings Co., Ltd., the holding company for the
Otsuka Group.

SPRYCEL is a registered trademark of Bristol-Myers Squibb
Company.

References

[1]. Macmillan Cancer Support. Leukaemia Overview. Available at:
http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Leukaemia/L
eukaemia overview.aspx. Last accessed April 2011

(Due to the length of this URL, it may be necessary to copy and
paste this hyperlink into your Internet browser's URL address field.
Remove the space if one exists.)

[2]. National Comprehensive Cancer Network (NCCN). Chronic
Myelogenous Leukemia - Clinical Practice Guidelines in Oncology -
v.1.2007.

[3]. Baccarani, M. and Dreyling, M. Annals of Oncology.
2010;21:165-167.

---------------------------------

[*] Glivec(R) (imatinib mesylate) is a registered trademark of
Novartis AG.

ots Originaltext: Bristol-Myers Squibb GmbH & Co.KG aA
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Contacts: Bristol-Myers Squibb: European Media Contact:
ElzbietaZawislak, +33615523580, elzbieta.zawislak@bms.com; Global
Media Contact:Sarah Koenig, +1-609-252-4145, sarah.koenig@bms.com